Adj. EBITA SEK 211m (-13% vs. ABGSCe 241m) Consensus EBITA likely to come down by 5-7% 10x 2023e EBI...
Redeye provides an initial comment on the Q3 2023 report from Scandinavian ChemoTech.
Redeye is shocked to learn that one of Alelion's largest customers is refusing to fulfil its part of...
Hansa publishes strong results 5-year after a kidney transplant supported by Idefirix.
Redeye comments on Invisio ahead of its Q3-results (due 25 October) where we expect continued strong...
Ahead of NoHo's Q3 report, we incorporate its latest acquisitions into our estimates.
Order intake likely to start stabilising Healthy balance sheet helpful to gain market share '23e-'25...
We cut '23e-'25e adj. EBITA by 14-5% Negative price/mix from inflation data continues Trading at '23...
Few order announcements put some risk on Q3e sales.
Redeye provides more color on Eniros prelimianary profit announcement.
Redeye is positive about ISAB’s new order worth EUR188,900 from a global generics manufacturer.
Försening i ConfIdes-studien Hansa kom under förra veckan med en bolagsuppdatering.
ChromoGenics announced last night that thay received an order of SEK5m for ConverLight dynamic glass...
Redeye is favorable to the news that Lifeclean has appointed a new permanent CEO.
Redeye takes a positive stance regarding Kontigo Care’s proposed directed share issue of approximate...
Q3e sales SEK 221m, up 11%, adj. EBITA margin 7.2% (8.
Reser betydande kapital Egetis meddelade under tisdagskvällen att de reser 462 mkr, varav 172 mkr ge...
Alltainer meddelade den 3 oktober att bolaget har beslutat att genomföra en nyemission av aktier med...
On 12 October, Fiskars lowered its adjusted EBIT guidance for 2023 from EUR 120-130m to EUR 100-120m...
We lower adjusted EBIT by 1-2% for 2023E-25E ahead of Elanders' Q3 2023 report.
